Eterna Therapeutics Inc. (ERNA) - Utang jangka dawa marang modal

Eterna Therapeutics (ERNA) price action on the GURU.Markets platform demonstrates metrics where long-term debt stands at 0.06. The brand is renowned for its authoritative developments in cell modification and RNA therapy for genetic blood pathologies. Cash flow relies on investments and research contracts. The business model combines the implementation of engineering platforms with the licensing of innovations through partnership agreements without conducting mergers.

This metric determines the ratio of long-term liabilities to equity, assessing the financial stability of the balance sheet structure. Investors use this metric to analyze the business's reliance on borrowed funds and the risks associated with debt servicing. The trend of the long-term debt-to-net assets ratio visualizes the level of debt load. For Eterna Therapeutics (ERNA), the absence of debt is expected, as the company focuses on patent protection. The venture funding model for early-stage development precludes the use of traditional debt instruments.